Positive patient experiences with the AUGMENT treatment

18.06.2015

Ovascience announced that physicians continue to report improvements in pregnancy rates and live births with the AUGMENT treatment in women with very poor prognoses, including those with poor egg health and embryo quality. At a scientific symposium held during the European Society for Human Reproduction and Embryology (ESHRE) annual meeting, fertility experts discussed the importance of egg health for improving patient care and shared their patients’ experiences using the AUGMENT treatment during in vitro fertilization (IVF). The AUGMENT treatment is not available in the United States.

During the conference, Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience, said, “We were pleased to host fertility specialists from more than forty countries at our scientific session, which focused on improving egg health and featured additional positive patient experiences with the AUGMENT treatment. The clinical pregnancy rates and live births reported by physicians using the AUGMENT treatment are encouraging, and we look forward to more patients having access to the treatment.”

At the scientific symposium entitled, “Experts in Egg Health: Advancing Fertility Patient Care,” physicians from leading clinics offering the AUGMENT treatment shared positive experiences in patients who had very poor prognoses and highlighted case studies of some of their most difficult-to-treat patients.

Michael Fakih, M.D., Founder and Chairman of Fakih IVF, a leading clinic in the United Arab Emirates (UAE), reported his patients’ experiences for the first time:

Dr. Fakih’s clinical experience showed positive results from 59 women with poor egg health and embryo quality who were given the AUGMENT treatment during IVF.
The average age of these women was 37.3 years, and they had an average of 4.3 prior IVF cycles.
Importantly, prior to using the AUGMENT treatment, the women had a combined 4 percent clinical pregnancy rate1 and a two percent live birth rate based on a combined total of 257 previous IVF cycles.
With the AUGMENT treatment, the patients’ combined clinical pregnancy rates increased at least five-fold.

“We offered the AUGMENT treatment to some of the most difficult-to-treat IVF patients who had a variety of factors impacting their ability to achieve a successful pregnancy,” said Dr. Fakih. “In spite of their poor prognoses, we saw clinical pregnancy rates climb to 22% from a 4% rate based on their combined prior IVF cycles. This is convincing evidence of the benefit of the AUGMENT treatment, and we are expanding on these initial experiences to include many more patients.”

At the scientific symposium presented updated patient experience and shared the news of the first birth in Turkey by a woman who received the AUGMENT treatment. The healthy baby girl was born to a mother who had failed 7 previous IVF cycles and had never achieved a pregnancy.

Based on: streetinsider.com